Role of Montelukast in the Treatment of Acute COVID-19

Widely Available Generic Perfect Fit for Multidrug Ambulatory Protocols

By Peter A. McCullough, MD, MPH

One of the most remarkable men in the early treatment camp for COVID-19 is South African hero, Dr. Shankaran Chetty. Early in the pandemic, I was fortunate to learn from him how to treat acute ambulatory COVID-19 without the use of hydroxychloroquine or ivermectin. Chetty relied on the principles of timing the illness for cytokine storm and then deploying a combination of anti-inflammatories, antihistamines, steroids, and anticoagulants. Among them is montelukast (Singulair), a leukotriene receptor antagonist used as part of an asthma therapy regimen, to prevent exercise induced bronchoconstriction, and treat acute asthma. Although in the first year of the crisis, there was insufficient evidence for montelukast to be listed in the McCullough Protocol. By 2021, I was using it widely in the acute treatment of COVID-19 with good success.